|
Press Releases |
|
 |
|
Wednesday, April 9, 2025 |
|
SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis |
SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce our breakthrough topline results from the completed Phase 1b clinical study evaluating SM17, a novel investigational therapy targeting the IL-25 (IL-17E) receptor pathway in moderate to severe atopic dermatitis (AD). more info >> |
|
Tuesday, April 16, 2024 |
|
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy |
SinoMab BioScience announced preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy. more info >> |
|
Tuesday, September 12, 2023 |
|
SinoMab's IND Application of SM17 has once again Received Approval from NAMP |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, August 14, 2023 |
|
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, June 12, 2023 |
|
SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, May 22, 2023 |
|
SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE |
A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
Monday, December 19, 2022 |
|
SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards" |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
Friday, November 4, 2022 |
|
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
Wednesday, August 24, 2022 |
|
Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
Friday, July 8, 2022 |
|
SinoMab Received the Highest Subsidy from HKSTP |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Hong Kong Book Fair, Sports and Leisure Expo and World of Snacks to reopen earlier at 9am tomorrow with extended evening hours
Jul 20, 2025 17:53 HKT/SGT
|
|
|
Typhoon special arrangements for Hong Kong Book Fair, Hong Kong Sports and Leisure Expo and World of Snacks
Jul 19, 2025 21:09 HKT/SGT
|
|
|
International Land Alliance Unveils New Revenue Model Featuring 100 Rental Homes in Cabo Oasis
Jul 18, 2025 21:00 HKT/SGT
|
|
|
Virturo Broker Launches Enhanced AI-Powered Trading Suite at London Investor Summit
Jul 18, 2025 17:00 HKT/SGT
|
|
|
Doubleview Gold Corp Provides Comprehensive Update on Its Flagship Project - the Polymetallic Hat Deposit
Jul 18, 2025 14:09 HKT/SGT
|
|
|
Honda Koraidon First Showrun during Suzuka 8 Hours
Jul 18, 2025 11:06 JST
|
|
|
SJC2 optical submarine cable in operation
Jul 18, 2025 9:36 JST
|
|
|
Latest GA Autonomous Jet Demo Features Live Air-to-Air Engagement Capability
Jul 18, 2025 00:05 HKT/SGT
|
|
|
Belgian Aircrew Completes MQ-9B Training
Jul 18, 2025 00:05 HKT/SGT
|
|
|
A New Transatlantic Partnership for European CCA
Jul 18, 2025 00:00 HKT/SGT
|
|
|
IP Roundtable and International Publishing Forum held at Hong Kong Book Fair today
Jul 17, 2025 20:32 HKT/SGT
|
|
|
Cornerstone Robotics Signs MOU with NHG Health and NTU Singapore to Facilitate Accessibility of RAS to Patients in Singapore
Jul 17, 2025 18:45 HKT/SGT
|
|
|
MHI-AP Awarded Long-term Service Contract for the Garabogazkarbamid Fertilizer Plant in Turkmenistan
Jul 17, 2025 19:07 JST
|
|
|
Mitsubishi Motors Premieres the All-New Destinator in Indonesia
Jul 17, 2025 17:21 JST
|
|
|
Hitachi, global investment firm Brookfield, and global commodities trading firm Hartree Begin to Explore a Funding Scheme in the Environmentally-friendly Digital Infrastructure Sector
Jul 17, 2025 14:16 JST
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|